No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
dactinomycin Sensitive: A1 - Approval
|
dactinomycin Sensitive: A1 - Approval
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
IE Sensitive: A2 - Guideline
|
IE Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
VAC Sensitive: A2 - Guideline
|
VAC Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine Sensitive: A2 - Guideline
|
doxorubicin hydrochloride + cyclophosphamide + etoposide IV + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
trabectedin Sensitive: A2 - Guideline
|
trabectedin Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
ADX-2191 Sensitive: A2 - Guideline
|
ADX-2191 Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
vinorelbine Sensitive: A2 - Guideline
|
vinorelbine Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
topotecan Sensitive: A2 - Guideline
|
topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
irinotecan Sensitive: A2 - Guideline
|
irinotecan Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
SA033 Sensitive: A2 - Guideline
|
SA033 Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline
|
temozolomide + irinotecan + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
cyclophosphamide + vinorelbine tartrate Sensitive: A2 - Guideline
|
cyclophosphamide + vinorelbine tartrate Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
carboplatin + etoposide oral Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
vincristine + dactinomycin Sensitive: A2 - Guideline
|
vincristine + dactinomycin Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
irinotecan + vincristine Sensitive: A2 - Guideline
|
irinotecan + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
doxorubicin hydrochloride + ifosfamide Sensitive: A2 - Guideline
|
doxorubicin hydrochloride + ifosfamide Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
cyclophosphamide + topotecan Sensitive: A2 - Guideline
|
cyclophosphamide + topotecan Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
doxorubicin hydrochloride + ifosfamide + vincristine Sensitive: A2 - Guideline
|
doxorubicin hydrochloride + ifosfamide + vincristine Sensitive: A2 - Guideline
|
No biomarker
|
Rhabdomyosarcoma
|
No biomarker
|
Rhabdomyosarcoma
|
doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine Sensitive: A2 - Guideline
|
doxorubicin hydrochloride + ifosfamide + cyclophosphamide + vincristine Sensitive: A2 - Guideline
|
PD-L1 expression
|
Rhabdomyosarcoma
|
PD-L1 expression
|
Rhabdomyosarcoma
|
nivolumab Sensitive: C1 - Off-label
|
nivolumab Sensitive: C1 - Off-label
|
BRAF-MAD1L1 fusion
|
Rhabdomyosarcoma
|
BRAF-MAD1L1 fusion
|
Rhabdomyosarcoma
|
anlotinib Resistant: C4 – Case Studies
|
anlotinib Resistant: C4 – Case Studies
|
PD-L1 expression
|
Rhabdomyosarcoma
|
PD-L1 expression
|
Rhabdomyosarcoma
|
pazopanib Resistant: C4 – Case Studies
|
pazopanib Resistant: C4 – Case Studies
|
HRAS mutation
|
Rhabdomyosarcoma
|
HRAS mutation
|
Rhabdomyosarcoma
|
tipifarnib Sensitive: D – Preclinical
|
tipifarnib Sensitive: D – Preclinical
|
KDM1A overexpression
|
Rhabdomyosarcoma
|
KDM1A overexpression
|
Rhabdomyosarcoma
|
SP2577 Sensitive: D – Preclinical
|
SP2577 Sensitive: D – Preclinical
|
PAX3-FOXO1 fusion
|
Rhabdomyosarcoma
|
PAX3-FOXO1 fusion
|
Rhabdomyosarcoma
|
SNDX-275 Sensitive: D – Preclinical
|
SNDX-275 Sensitive: D – Preclinical
|
HER-2 expression
|
Rhabdomyosarcoma
|
HER-2 expression
|
Rhabdomyosarcoma
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
|